• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Biogen Inc.

    6/2/25 9:20:36 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BIIB alert in real time by email
    DEFA14A 1 d944881ddefa14a.htm DEFA14A DEFA14A
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 14A

    (Rule 14a-101)

    INFORMATION REQUIRED IN PROXY STATEMENT

    SCHEDULE 14A INFORMATION

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

     

     

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐

    Definitive Proxy Statement

     

    ☒

    Definitive Additional Materials

     

    ☐

    Soliciting Material Pursuant to §240.14a-12

    BIOGEN INC.

    (Name of Registrant as Specified In Its Charter)

    (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒

    No fee required.

     

    ☐

    Fee paid previously with preliminary materials.

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11.

     

     
     


    Dear Fellow Stockholders,

    Ahead of the annual meeting of Biogen Inc. (“Biogen” or the “Company”) on June 17, 2025, the Board of Directors (the “Board”) and Compensation and Management Development Committee (the “CMDC”) want to express our appreciation for our stockholders’ consistent support of the Company over many years.

    The Board has provided oversight of our long-term strategy to create sustainable stockholder value, while the CMDC has continuously improved our compensation program to align with Company performance and stockholder value. Our executive compensation program is designed to attract and retain the talented and experienced management team required to achieve our goals.

    Biogen’s Ongoing Transformation Focused on Delivering Long-Term Stockholder Value

    We embarked on a multi-year transformational journey in 2023 to achieve our goal of long-term sustainable growth under the leadership of our Chief Executive Officer (“CEO”), Chris Viehbacher, who joined us in November 2022. Biogen’s vision and actions include:

     

      •  

    Instituting a portfolio transition that shifts focus from legacy products to growth areas.

     

      •  

    Reducing and redeploying the company cost base.

     

      •  

    Focusing the Research and Development portfolio on value creating programs; and

     

      •  

    Seeking and executing on external growth opportunities.

    These actions create a foundation for future growth and we look forward to key pipeline readouts that begin in 2026. We believe our executive compensation philosophy properly reflects this context, aligning total compensation with long term value creation and Total Shareholder Return (“TSR”), while also recognizing the achievement of near-term milestones with the Short-Term Incentive (“STI”) program design.

    In 2024, the Company achieved key milestones including:

     

      •  

    Executed on four new product launches that we believe align with our strongest potential growth drivers.

     

      •  

    Further developed our potentially transformative pipeline through internal development efforts as well as external strategic transactions; and

     

      •  

    Exercised strong financial discipline to reduce and redeploy our cost base, expecting to deliver gross operating expense savings of approximately $1 billion by the end of 2025.

    While these achievements demonstrate significant progress in the second year of this transformation, our stock performance reflects our current stage in this transition.


    The CMDC’s Approach to Compensation Has Resulted in Rigorous Pre-defined Goals to Reward Short- and Long-Term Performance

    The CMDC remains committed to our pay-for-performance philosophy and the belief that our executive compensation outcomes should align with stockholders’ expectations and returns. This philosophy is reflected in our 2024 executive compensation program design, underpinned by strong governance. Our incentive goals are set in advance every year and are designed to align near- and long-term performance expectations.

    As in prior years, the CMDC set Biogen’s 2024 executive compensation incentive program targets with discipline and rigor. Short- and long-term financial goals were set in line with guidance provided to the market. The CMDC also set pipeline milestones and certain corporate responsibility goals to represent Biogen’s culture and commitment to patients. All these elements are critical to near- and long-term value creation.

     

      •  

    Biogen has exceeded analyst EPS expectations in three of the last four fiscal years (2024, 2022 and 2021, respectively). The 2024 STI achievement of the total compensation is aligned with such financial management performance and demonstrates alignment of the goals to drive performance beyond analysts’ expectations.

     

      •  

    Biogen’s 2024 performance included four product launches we believe will contribute to near- and long-term sustainable growth, and that delivered $547M in incremental revenue. Our continued pipeline development included the acquisition of Human Immunology Biosciences, Inc., and its drug candidate felzartamab with potential across multiple rare immunology indications.

     

      •  

    The 2024 STI payout recognized achievement of these positive milestones, disciplined execution, cost reductions and moving Biogen forward toward our multi-year strategic goals.

     

      •  

    Total compensation for our CEO and executives declined meaningfully in 2024 as the result of the Long-Term Incentive (“LTI”) program design. As outlined in our proxy filing, 80% of our CEO’s pay and 70% of our other Named Executive Officers (“NEOs”) pay is comprised of stock-based compensation. The PSU award which vested in 2024 had a $0 payout.

     

      •  

    As of December 31, 2024, our pay programs have resulted in a CEO total realizable compensation reduction of 66% from the awarded compensation, as illustrated below, demonstrating that our programs are aligned with stockholder experience and our total compensation pay-for-performance design is working as intended.


    LOGO

    Beyond these realizable pay consequences, Biogen’s executive stock ownership guidelines require our NEOs to maintain a minimum of three times their base salaries, and our CEO to maintain a minimum of six times his base salary. Our stock performance has reduced the value of our executives’ stock holdings.

    In addition to Company goals, our executives are held to rigorous individual performance goals. Goal achievement is measured at the conclusion of the year based on quantitative and qualitative performance metrics established for the pre-defined goals. The CMDC believes that individual performance goals further drive direct accountability of each executive’s remit and contribution to Biogen’s collective achievements.

    Our CEO’s goals are approved by the Board at the beginning of each year. The CMDC remains committed to setting robust targets to drive the creation of long-term value for Biogen stockholders.

    Our Pay Benchmarking Practices Appropriately Incentivizes and Rewards Executives

    Pay practices for our executives, including our CEO, are benchmarked against our executive compensation peer group, comprised of 15 companies within the biotechnology/pharmaceutical sector. This peer group has remained largely constant over the last three years, apart from acquisition activity within the group, and is reflective of Biogen’s profile in terms of size, maturity, global scale, and complexity. Relative to this peer group, Biogen is at median on revenue and 35th percentile on market cap indicating reasonable alignment and consistency with market practices.

    Most importantly, this group reflects the executive talent pool from which Biogen attracts and retains talent. Our executive hiring has been directly sourced from many of the biopharmaceutical organizations within this group, and therefore, we must be competitive in compensation practices by benchmarking against this group.


    Biogen’s Commitment to Stockholder Responsiveness is Evidenced in Pay Design

    Reflecting the value the CMDC and Board place on stockholder feedback, over the last several years, independent Directors have consistently engaged with stockholders to understand their perspectives and gather feedback on our executive compensation programs. In response to feedback received, the CMDC made changes to our executive LTI program in 2024 including:

     

      •  

    Increased the weighting of PSUs in the LTI mix from 50% to 60%, while also aligning the benchmark from 55th to 50th percentile for relative TSR consistent with most of our peers.

     

      •  

    Added an EPS compound annual growth rate (“CAGR”) metric into the PSU measurement to incorporate an objective operating metric which management is incentivized to achieve; and

     

      •  

    Introduced an expanded relative TSR peer group based on a broader biotech index.

    We do not disclose our forward-looking EPS CAGR targets, which is consistent with industry practice, since such disclosure could be interpreted as premature guidance and potentially competitively harmful. We will continue to disclose performance achievement at the end of the 3-year performance period.

    In 2024, stockholders recognized the alignment of our executive compensation program with Company performance and the creation of long-term stockholder value by overwhelmingly supporting our Say on Pay proposal, as evidenced by the over 95% vote in favor of our proposal.

    We will continue to solicit feedback regarding our executive compensation programs to ensure strong stockholder alignment.

    Conclusion

    The CMDC is intentional in its design of Biogen’s compensation programs, enabling the Company to attract and retain the talent required to drive sustainable growth, properly reward near term milestones and provide total compensation that aligns with shareholder value. An important part of that design is setting rigorous goals that align with such objectives and follow a well-defined governance process.

    The executive compensation program administered for 2024 remains consistent with our compensation philosophies and was informed by feedback from our stockholders.

    We appreciate your continued support and request stockholders to vote in line with all Board recommendations including voting “FOR” the Say-on-Pay proposal.

    Thank you,

    The CMDC on behalf of the Board of Directors

    Get the next $BIIB alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $BIIB

    DatePrice TargetRatingAnalyst
    7/21/2025$142.00Hold
    Truist
    4/28/2025$118.00Buy → Hold
    HSBC Securities
    4/4/2025Buy → Hold
    Argus
    2/11/2025$160.00Mkt Perform
    Bernstein
    1/2/2025$315.00 → $138.00Overweight → Neutral
    Piper Sandler
    12/20/2024$230.00 → $164.00Outperform → Market Perform
    BMO Capital Markets
    12/16/2024$175.00Buy → Hold
    Stifel
    12/10/2024$178.00Neutral
    BofA Securities
    More analyst ratings

    $BIIB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Truist resumed coverage on Biogen with a new price target

      Truist resumed coverage of Biogen with a rating of Hold and set a new price target of $142.00

      7/21/25 8:31:03 AM ET
      $BIIB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Biogen downgraded by HSBC Securities with a new price target

      HSBC Securities downgraded Biogen from Buy to Hold and set a new price target of $118.00

      4/28/25 8:32:10 AM ET
      $BIIB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Biogen downgraded by Argus

      Argus downgraded Biogen from Buy to Hold

      4/4/25 7:48:30 AM ET
      $BIIB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BIIB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Biogen to Highlight Scientific Progress Across Alzheimer's Disease at the Alzheimer's Association International Conference 2025

      Lecanemab presentations to include long-term Clarity AD data, real-world treatment insights, and a subcutaneous formulation for continued carePresentations on tau to explore its biological role, the development of targeted therapies and biomarkers, and the future integration of these innovations into clinical practice CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) today announced upcoming scientific presentations at the 2025 Alzheimer's Association International Conference (AAIC), taking place July 27-31 in Toronto, Canada. Data on LEQEMBI® (lecanemab) will include 48-month results from the Clarity AD open-label extension, real-world evidence, and new insigh

      7/21/25 7:30:00 PM ET
      $BIIB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Biogen Announces $2 Billion Manufacturing Investment in North Carolina's Research Triangle Park in Conjunction with its 30th Anniversary

      Investment builds on Biogen's 30-year history of manufacturing in the region, with approximately $10 billion invested to date CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) – today announced it intends to invest an additional $2 billion in its existing manufacturing footprint in North Carolina's Research Triangle Park (RTP). Since breaking ground in 1995, Biogen's manufacturing in RTP has played a vital role in delivering the company's pipeline and portfolio of innovative treatments for millions of patients around the world. Biogen has invested approximately $10 billion in its North Carolina manufacturing footprint to date, including more than $3 billion in

      7/21/25 7:30:00 AM ET
      $BIIB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Stoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress

      – Data from an analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed improvements in cognition and behavior at Week 68 – – These findings support the inclusion of key secondary endpoints assessing cognition and behavior in the Phase 3 EMPEROR study and contrast with outcomes observed in natural history data – Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, and Biogen Inc. (NASDAQ:BIIB) today announced the presentation of data from an analysis that informed the design of the Phase 3 EMPEROR study and evaluated the potential effect

      7/10/25 7:00:00 AM ET
      $BIIB
      $STOK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $BIIB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Dorsa Caroline bought $151,559 worth of shares (1,235 units at $122.72), increasing direct ownership by 5% to 27,842 units (SEC Form 4)

      4 - BIOGEN INC. (0000875045) (Issuer)

      5/5/25 4:17:10 PM ET
      $BIIB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Rowinsky Eric K bought $101,256 worth of shares (455 units at $222.54), increasing direct ownership by 2% to 20,629 units (SEC Form 4)

      4 - BIOGEN INC. (0000875045) (Issuer)

      2/20/24 9:13:26 PM ET
      $BIIB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BIIB
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for VUMERITY issued to BIOGEN INC

      Submission status for BIOGEN INC's drug VUMERITY (ORIG-1) with active ingredient DIROXIMEL FUMARATE has changed to 'Approval' on 09/12/2024. Application Category: NDA, Application Number: 761347, Application Classification: Type 3 - New Dosage Form

      9/16/24 6:52:10 AM ET
      $BIIB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for VUMERITY issued to BIOGEN INC

      Submission status for BIOGEN INC's drug VUMERITY (SUPPL-17) with active ingredient DIROXIMEL FUMARATE has changed to 'Approval' on 09/11/2024. Application Category: NDA, Application Number: 211855, Application Classification: Manufacturing (CMC)

      9/16/24 6:24:32 AM ET
      $BIIB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for VUMERITY issued to BIOGEN INC

      Submission status for BIOGEN INC's drug VUMERITY (SUPPL-15) with active ingredient DIROXIMEL FUMARATE has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211855, Application Classification: Labeling

      3/25/24 4:41:37 AM ET
      $BIIB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BIIB
    SEC Filings

    See more
    • Biogen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - BIOGEN INC. (0000875045) (Filer)

      7/7/25 4:10:34 PM ET
      $BIIB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Biogen Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - BIOGEN INC. (0000875045) (Filer)

      6/23/25 4:18:57 PM ET
      $BIIB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Biogen Inc.

      DEFA14A - BIOGEN INC. (0000875045) (Filer)

      6/2/25 9:20:36 AM ET
      $BIIB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BIIB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Head of Global Product Strat. Izzar Rachid sold $300,105 worth of shares (2,223 units at $135.00), decreasing direct ownership by 26% to 6,330 units (SEC Form 4)

      4 - BIOGEN INC. (0000875045) (Issuer)

      7/16/25 5:55:39 PM ET
      $BIIB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Pangalos Menelas N

      4 - BIOGEN INC. (0000875045) (Issuer)

      6/18/25 5:05:17 PM ET
      $BIIB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Minor Lloyd was granted 2,370 shares (SEC Form 4)

      4 - BIOGEN INC. (0000875045) (Issuer)

      6/18/25 4:54:06 PM ET
      $BIIB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BIIB
    Financials

    Live finance-specific insights

    See more
    • Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results

      Salanersen (BIIB115/ION306) is a novel antisense oligonucleotide (ASO) with the potential to achieve high efficacy and once yearly dosing in spinal muscular atrophy (SMA)Interim Phase 1 data show children with SMA previously treated with gene therapy experienced a substantial slowing of neurodegeneration and clinically meaningful improvements in motor function following initiation of salanersenBased on these encouraging Phase 1 data, Biogen is engaging with regulators to advance salanersen to registrational stage studies, building on extensive experience in SMA CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) announced topline results from the Phase 1 study of

      6/25/25 7:30:37 AM ET
      $BIIB
      $IONS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Organon Acquires TOFIDENCE™ (tocilizumab-bavi), a Commercialized Biosimilar to ACTEMRA® (tocilizumab) Injection, for Intravenous Infusion in the U.S.

      Strengthens and expands U.S. biosimilars immunology portfolio with multi-indication arthritis treatment Organon (NYSE:OGN), a global healthcare company with a deep expertise in biosimilars, today announced that it has acquired from Biogen Inc. (NASDAQ:BIIB) regulatory and commercial rights in the U.S. for TOFIDENCE™, a biosimilar to ACTEMRA®, for intravenous infusion. TOFIDENCE, the first approved tocilizumab biosimilar entrant in the U.S. market, was launched in May 2024 and is indicated in certain patients for the treatment of moderately to severely active rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and

      4/1/25 7:30:00 AM ET
      $BIIB
      $OGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • GeneDx Reports Fourth Quarter and Full Year 2024 Financial Results and Issues Guidance for Full Year 2025

      Grew fourth quarter 2024 revenues1 to $95.3 million Expanded fourth quarter 2024 adjusted gross margins1,2 to 70% Generated fourth quarter 2024 adjusted net income2 of $16.8 million FY 2025 revenue guidance of $350M to $360M, exome/genome volume and revenue growth of at least 30% GeneDx to host conference call today at 8:30 a.m. ET GeneDx Holdings Corp. (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the fourth quarter and full year of 2024. "The fourth quarter capped an outstanding year for GeneDx, as we work to end the diagnostic odyssey with earlier intervention using our industry-leading exome and gen

      2/18/25 6:00:00 AM ET
      $BIIB
      $PRAX
      $STOK
      $WGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Retail: Computer Software & Peripheral Equipment

    $BIIB
    Leadership Updates

    Live Leadership Updates

    See more
    • Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

      BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced the appointment of Maha Radhakrishnan, M.D., to its Board of Directors. "We are pleased to have Dr. Radhakrishnan join the Board at this time of tremendous clinical momentum at Entrada, led by the continued advancement of our Duchenne muscular dystrophy franchise. Dr. Radhakrishnan's deep and meaningful experience in global drug development will be invaluable as we quickly advance our novel Duchenne programs into multiple patient-focused clinical trials throughout this year," said Dipal Doshi, Chief Executive Officer at Entrada Therapeutics. "I'm honored to join the Board of Entrada

      6/3/25 7:00:00 AM ET
      $BIIB
      $TRDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Cardurion Pharmaceuticals Appoints Karen Lewis as Chief People Officer

      Cardurion Pharmaceuticals, Inc. ("Cardurion"), a clinical-stage biotechnology company discovering and developing new therapeutic approaches for the treatment of cardiovascular diseases, today announced that Karen Lewis has joined the company as Chief People Officer. She joins Cardurion with more than 25 years of experience in human resources helping to build organizations and develop programs that support companies at various stages of growth. She most recently was Chief People Officer at Apellis Pharmaceuticals (NASDAQ:APLS) during a period of rapid growth, and previously held leadership roles in human resources at Biogen (NASDAQ:BIIB) and Bristol-Myers Squibb (NYSE:BMY). "We're delighted

      3/20/25 8:00:00 AM ET
      $APLS
      $BIIB
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Cardurion Pharmaceuticals Appoints Charlotte Newman as Chief Business Officer

      Cardurion Pharmaceuticals, Inc. ("Cardurion"), a clinical-stage biotechnology company discovering and developing new therapeutic approaches for the treatment of cardiovascular diseases, today announced that Charlotte (Charlie) Newman has joined the company as Chief Business Officer. A biopharmaceutical industry executive with over 25 years of industry experience, Ms. Newman most recently led corporate, portfolio and program strategy and business development as Chief Business Officer of Agios Pharmaceuticals (NASDAQ:AGIO), and previously held strategic product and portfolio roles at Biogen (NASDAQ:BIIB). In her role at Cardurion, she will be responsible for leading corporate development, bus

      1/8/25 8:00:00 AM ET
      $AGIO
      $BIIB
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $BIIB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Biogen Inc.

      SC 13G/A - BIOGEN INC. (0000875045) (Subject)

      11/12/24 1:24:28 PM ET
      $BIIB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Biogen Inc.

      SC 13G/A - BIOGEN INC. (0000875045) (Subject)

      11/4/24 11:20:12 AM ET
      $BIIB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Biogen Inc.

      SC 13G - BIOGEN INC. (0000875045) (Subject)

      10/16/24 12:11:53 PM ET
      $BIIB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care